455 related articles for article (PubMed ID: 2120551)
1. Evaluation of live trivalent vaccine of measles AIK-C strain, mumps Hoshino strain and rubella Takahashi strain, by virus-specific interferon-gamma production and antibody response.
Nakayama T; Urano T; Osano M; Nakagawa M; Maehara N; Sasaki K; Yamamura AM; Makino S
Microbiol Immunol; 1990; 34(6):497-508. PubMed ID: 2120551
[TBL] [Abstract][Full Text] [Related]
2. A new combined trivalent live measles (AIK-C strain), mumps (Hoshino strain), and rubella (Takahashi strain) vaccine. Findings in clinical and laboratory studies.
Makino S; Sasaki K; Nakayama T; Oka S; Urano T; Kimura M; Kawana R; Yamamura AM
Am J Dis Child; 1990 Aug; 144(8):905-10. PubMed ID: 2198807
[TBL] [Abstract][Full Text] [Related]
3. [Clinico-immunologic evaluation of a trivalent vaccine against measles, rubella and mumps].
Schettini F; Manzionna MM; De Mattia D; Amendola F; Di Bitonto G
Minerva Pediatr; 1989 Mar; 41(3):117-22. PubMed ID: 2747598
[TBL] [Abstract][Full Text] [Related]
4. Response to measles-mumps-rubella vaccine in children on dialysis.
Schulman SL; Deforest A; Kaiser BA; Polinsky MS; Baluarte HJ
Pediatr Nephrol; 1992 Mar; 6(2):187-9. PubMed ID: 1571219
[TBL] [Abstract][Full Text] [Related]
5. [Experience with preventive measles, mumps and rubella vaccination in unified Germany].
Gerike E; Tischer A
Gesundheitswesen; 1993 Jan; 55(1):38-9. PubMed ID: 8435543
[TBL] [Abstract][Full Text] [Related]
6. A field with a liver measles-mumps-rubella vaccine.
Walters VW; Miller SA; Jackson JE; Kenny MT
Clin Pediatr (Phila); 1975 Oct; 14(10):928-33. PubMed ID: 1100294
[TBL] [Abstract][Full Text] [Related]
7. Immune response after primary and re-vaccination with different combined vaccines against measles, mumps, rubella.
Tischer A; Gerike E
Vaccine; 2000 Jan; 18(14):1382-92. PubMed ID: 10618536
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of a two-dose measles, mumps, and rubella vaccination schedule in a cohort of college athletes.
Coté TR; Sivertson D; Horan JM; Lindegren ML; Dwyer DM
Public Health Rep; 1993; 108(4):431-5. PubMed ID: 8341775
[TBL] [Abstract][Full Text] [Related]
9. Antibody persistence after primary measles-mumps-rubella vaccine and response to a second dose given at four to six vs. eleven to thirteen years.
Johnson CE; Kumar ML; Whitwell JK; Staehle BO; Rome LP; Dinakar C; Hurni W; Nalin DR
Pediatr Infect Dis J; 1996 Aug; 15(8):687-92. PubMed ID: 8858673
[TBL] [Abstract][Full Text] [Related]
10. Two doses of MMR vaccine--sufficient to eradicate measles, mumps and rubella?
Fahlgren K
Scand J Soc Med; 1988; 16(3):129-35. PubMed ID: 3057621
[TBL] [Abstract][Full Text] [Related]
11. Interference between strains in live virus vaccines, I: Combined vaccination with measles, mumps and rubella vaccine.
Berger R; Just M; Glück R
J Biol Stand; 1988 Oct; 16(4):269-73. PubMed ID: 3198657
[TBL] [Abstract][Full Text] [Related]
12. Clinical evaluation of a new measles-mumps-rubella combined live virus vaccine in the Dominican Republic.
Ehrenkranz NJ; Ventura AK; Medler EM; Jackson JE; Kenny MT
Bull World Health Organ; 1975; 52(1):81-5. PubMed ID: 764997
[TBL] [Abstract][Full Text] [Related]
13. Changes of the immunological patterns against measles, mumps and rubella. A vaccination programme studied 3 to 7 years after the introduction of a two-dose schedule.
Christenson B; Böttiger M
Vaccine; 1991 May; 9(5):326-9. PubMed ID: 1872016
[TBL] [Abstract][Full Text] [Related]
14. Immunity to and immunization against measles, rubella and mumps in patients after autologous bone marrow transplantation.
Pauksen K; Duraj V; Ljungman P; Sjölin J; Oberg G; Lönnerholm G; Fridell E; Smedmyr B; Simonsson B
Bone Marrow Transplant; 1992 Jun; 9(6):427-32. PubMed ID: 1628126
[TBL] [Abstract][Full Text] [Related]
15. Clinical trial of a new trivalent measles-mumps-rubella vaccine in young children.
Vesikari T; Ala-Laurila EL; Heikkinen A; Terho A; D'Hondt E; André FE
Am J Dis Child; 1984 Sep; 138(9):843-7. PubMed ID: 6383020
[TBL] [Abstract][Full Text] [Related]
16. Antibody response to measles-mumps-rubella vaccine of children with mild illness at the time of vaccination.
King GE; Markowitz LE; Heath J; Redd SC; Coleman S; Bellini WJ; Sievert A
JAMA; 1996 Mar; 275(9):704-7. PubMed ID: 8594268
[TBL] [Abstract][Full Text] [Related]
17. [Field trial with a new human diploid cell vaccine (HDCV) against measles, mumps and rubella].
Just M; Berger R; Glück R; Wegmann A
Schweiz Med Wochenschr; 1985 Nov; 115(48):1727-30. PubMed ID: 4081704
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of vaccination of marrow transplant recipients with a live attenuated measles, mumps, and rubella vaccine.
Ljungman P; Fridell E; Lönnqvist B; Bolme P; Böttiger M; Gahrton G; Linde A; Ringdén O; Wahren B
J Infect Dis; 1989 Apr; 159(4):610-5. PubMed ID: 2647859
[TBL] [Abstract][Full Text] [Related]
19. Protection of mumps in children with various underlying diseases: application of a live attenuated mumps and trivalent measles-rubella-mumps (MRM) vaccines in these children.
Kanesaki T; Baba K; Tsuda N; Yabuuchi H; Yamanishi K; Takahashi M
Biken J; 1986 Dec; 29(3-4):63-71. PubMed ID: 3304276
[TBL] [Abstract][Full Text] [Related]
20. The elimination of indigenous measles, mumps, and rubella from Finland by a 12-year, two-dose vaccination program.
Peltola H; Heinonen OP; Valle M; Paunio M; Virtanen M; Karanko V; Cantell K
N Engl J Med; 1994 Nov; 331(21):1397-402. PubMed ID: 7969278
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
